drugset / Trial / NCT03902184
IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
Timeline
- Start
- 2019-05-22
- Primary completion
- 2026-01-08
- Completion
- 2026-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lacutamab | Monoclonal antibody | 750 mg | — |